Chenq Y News Today

Adding toripalimab to first-line chemotherapy improved survival in patients with recurrent or metastatic nasopharyngeal carcinoma. Adding toripalimab to first-line chemotherapy improved survival in patients with recurrent or metastatic nasopharyngeal carcinoma.

Nabil F. Saba, MD, FACP, and Shravan Kandula, MD, highlight the significance of the approval of toripalimab for nasopharyngeal carcinoma; key data from JUPITER-02 and POLARIS-02 trials; and how the addition of this agent to the treatment armamentarium heightens the importance of multidisciplinary collaboration.

First-line treatment with toripalimab in combination with gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs placebo plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma.